DE602005016683D1 - Genetisch modifizierte, menschliche, natürliche killerzellenlinien: - Google Patents

Genetisch modifizierte, menschliche, natürliche killerzellenlinien:

Info

Publication number
DE602005016683D1
DE602005016683D1 DE200560016683 DE602005016683T DE602005016683D1 DE 602005016683 D1 DE602005016683 D1 DE 602005016683D1 DE 200560016683 DE200560016683 DE 200560016683 DE 602005016683 T DE602005016683 T DE 602005016683T DE 602005016683 D1 DE602005016683 D1 DE 602005016683D1
Authority
DE
Germany
Prior art keywords
natural killer
modified
human
killer cell
cell lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE200560016683
Other languages
English (en)
Inventor
Kerry S Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fox Chase Cancer Center
Original Assignee
Fox Chase Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005016683(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fox Chase Cancer Center filed Critical Fox Chase Cancer Center
Publication of DE602005016683D1 publication Critical patent/DE602005016683D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
DE200560016683 2004-07-10 2005-07-08 Genetisch modifizierte, menschliche, natürliche killerzellenlinien: Active DE602005016683D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58658104P 2004-07-10 2004-07-10
PCT/US2005/024229 WO2006023148A2 (en) 2004-07-10 2005-07-08 Genetically modified human natural killer cell lines

Publications (1)

Publication Number Publication Date
DE602005016683D1 true DE602005016683D1 (de) 2009-10-29

Family

ID=35968029

Family Applications (1)

Application Number Title Priority Date Filing Date
DE200560016683 Active DE602005016683D1 (de) 2004-07-10 2005-07-08 Genetisch modifizierte, menschliche, natürliche killerzellenlinien:

Country Status (12)

Country Link
US (8) US7618817B2 (de)
EP (5) EP2801583B1 (de)
AT (1) ATE443084T1 (de)
AU (1) AU2005277831B2 (de)
CA (2) CA3052445C (de)
DE (1) DE602005016683D1 (de)
DK (4) DK2112162T3 (de)
ES (3) ES2955952T3 (de)
HK (2) HK1203975A1 (de)
PL (1) PL2921500T3 (de)
PT (1) PT2921500T (de)
WO (1) WO2006023148A2 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2112162T3 (da) 2004-07-10 2015-02-23 Fox Chase Cancer Ct Genetisk modificerede humane naturlige dræbercellelinjer
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
WO2008031056A2 (en) 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
JP5282040B2 (ja) * 2007-09-28 2013-09-04 オリンパス株式会社 Ｆｃ受容体遺伝子導入ＮＫ細胞を用いた抗体依存性細胞傷害のアッセイ方法
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009081201A2 (en) 2007-12-21 2009-07-02 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Rα) - 173
EP2161339A1 (de) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC mit modifizierten NK92-Zellen
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
DK3052192T3 (da) 2013-10-02 2020-09-28 Medimmune Llc Neutraliserende anti-influenza a-antistoffer og anvendelser deraf
EP4134085A1 (de) 2013-11-01 2023-02-15 ImmunityBio, Inc. Tumorizide und antimikrobielle zusammensetzungen und verfahren
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
AU2015235852B2 (en) * 2014-03-28 2019-08-15 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered CD16
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
US20170182292A1 (en) 2014-05-22 2017-06-29 Nantkwest, Inc. Treating solid tumours with nk-92 cells applied by microcatheter
US20170151283A1 (en) * 2014-05-23 2017-06-01 The Trustees Of The University Of Pennsylvania Compositions and methods for treating antibody resistance
JP2017525385A (ja) 2014-06-18 2017-09-07 ケモテラペウティシェス フォルシュングインスティトゥート ゲオルグ−シュパイヤー−ハウス 細胞治療物質としてのｃａｒ発現ｎｋ−９２細胞
EP3204020B1 (de) * 2014-10-06 2023-01-18 ImmunityBio, Inc. Behandlung von viralem hämorrhagischem fieber mit nk-92-zellen
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
JP2018509459A (ja) * 2015-03-27 2018-04-05 ナントクエスト インコーポレイテッド がん治療薬との併用療法におけるｎｋ−９２細胞
WO2016160602A2 (en) * 2015-03-27 2016-10-06 Nantkwest, Inc. Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer
CN108136021A (zh) 2015-04-25 2018-06-08 综合医院公司 用于治疗癌症的抗驱走性试剂和抗癌剂联合疗法和组合物
HUE056407T2 (hu) 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
EP3307876B1 (de) 2015-06-10 2023-09-13 ImmunityBio, Inc. Modifizierte nk-92-zellen zur behandlung von krebs
EP3317401B1 (de) 2015-07-29 2018-10-03 Onkimmune Limited Modifizierte natürliche killerzellen und natürliche killerzelllinien mit erhöhter zytotoxizität
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
CA2999083A1 (en) 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Localized delivery of anti-fugetactic agent for treatment of cancer
US10533157B1 (en) 2015-12-03 2020-01-14 Nantbio, Inc. Recombinant NK cells expressing co-stimulatory molecules
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017132202A1 (en) * 2016-01-25 2017-08-03 Nant Holdings Ip, Llc Nk cells with altered cxcl12/cxcr4 signaling
WO2017184534A1 (en) * 2016-04-18 2017-10-26 The Gorlin Companies Methods and compositions for improving safety and efficacy of natural killer cell immunotherapy
WO2017201432A2 (en) 2016-05-19 2017-11-23 Jounaidi Youssef Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
WO2018053270A1 (en) * 2016-09-16 2018-03-22 The General Hospital Corporation Modified natural killer cells for the treatment of cancer
JP2019532640A (ja) * 2016-09-29 2019-11-14 ナントクエスト インコーポレイテッド 免疫原性が低下したｈｌａクラスｉ欠損ｎｋ−９２細胞
EP3565565A4 (de) 2017-01-04 2020-12-09 Nova Southeastern University Natürliche killerzellen (nk) zur expression eines antigenspezifischen funktionalen t-zell-rezeptor (tcr)-komplexes, verfahren zur herstellung davon und verfahren zur therapeutischen verwendung davon
JP7118072B2 (ja) 2017-01-06 2022-08-15 イミュニティーバイオ インコーポレイテッド Ｃｄ９６／ｔｉｇｉｔ発現が低下した遺伝子改変型ｎｋ－９２細胞
EP3576791A4 (de) * 2017-02-01 2020-11-25 Nant Holdings IP, LLC Calreticulinvermittelte krebsbehandlung
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
CA3052473A1 (en) * 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
EP3592845A4 (de) * 2017-03-08 2020-12-30 Nantkwest, Inc. Modifizierte nk-92-hank003-zellen für die klinik
JP2020515542A (ja) 2017-03-23 2020-05-28 ザ ジェネラル ホスピタル コーポレイション Ｃｘｃｒ４／ｃｘｃｒ７の遮断およびヒトパピローマウイルス関連疾患の治療
US20200188433A1 (en) * 2017-03-27 2020-06-18 Nantcell, Inc. aNK AND IL-12 COMPOSITIONS AND METHODS
CN117384929A (zh) 2017-03-27 2024-01-12 新加坡国立大学 一种编码由细胞表达的嵌合受体的多核苷酸
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
WO2018191619A1 (en) * 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
KR20200035999A (ko) 2017-08-04 2020-04-06 난트케이웨스트, 인크. Nk-92 세포를 이용한 백혈병의 치료 및 억제
AU2018355462B9 (en) * 2017-10-26 2022-04-28 Regents Of The University Of Minnesota Recombinant immune cells, methods of making, and methods of use
WO2019084284A1 (en) 2017-10-27 2019-05-02 Coneksis, Inc. NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
WO2019089813A1 (en) 2017-11-01 2019-05-09 Nantkwest, Inc. Nk-92 cells to stimulate anti-cancer vaccine
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
WO2019152513A1 (en) 2018-01-31 2019-08-08 Nantkwest, Inc. Use of 5% human albumin in wash and harvest media
CA3091224A1 (en) 2018-03-12 2019-09-19 Nantkwest, Inc. Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
WO2019201629A1 (en) * 2018-04-19 2019-10-24 Onkimmune Limited Nk cells for use with antibodies in cancer therapy
JP2021522839A (ja) * 2018-05-14 2021-09-02 インダプタ セラピューティクス インコーポレイテッド 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット
JP7208262B2 (ja) * 2018-05-22 2023-01-18 イミュニティーバイオ インコーポレイテッド ポロキサマーを用いてｎｋ－９２細胞増殖を最適化する方法
KR20210011977A (ko) 2018-05-22 2021-02-02 난트케이웨스트, 인크. Nk-92 세포를 성장시키기 위한 기초 배지
CA3097904A1 (en) * 2018-05-22 2019-11-28 Nantkwest, Inc. Fc-epsilon car
EP3797149A1 (de) 2018-05-22 2021-03-31 Nantkwest, Inc. Verfahren und systeme zur zellbettbildung während der bioverarbeitung
WO2020014245A1 (en) 2018-07-10 2020-01-16 Nantkwest, Inc. Cryopreservation
IL296050B1 (en) 2018-08-01 2024-08-01 Immunitybio Inc A quadricistronic system containing a receptor or cytokine and a chimeric antigen receptor for genetic modification of immunotherapies
US20210293787A1 (en) 2018-08-01 2021-09-23 Nantkwest, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
AU2019371340B2 (en) 2018-10-31 2022-03-03 Nantkwest, Inc. Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cells
EP3746547A4 (de) * 2018-10-31 2021-12-01 Nantkwest, Inc. Entfernung von pd-l1-positiven malignomen durch chimäre pd-l1-antigenrezeptor-exprimierende nk-zellen
KR102569842B1 (ko) 2018-11-06 2023-08-23 난트퀘스트, 인크. 키메라 항원 수용체-변형된 nk-92 세포
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
AU2019388876A1 (en) 2018-11-26 2021-05-20 Immunitybio, Inc. IL-2 Dependent NK-92 cells with stable Fc receptor expression
KR20210108409A (ko) * 2018-12-20 2021-09-02 클레오 파마슈티컬스 인코포레이티드 Arm과 자연 살해 세포의 조합 요법
JP7335001B2 (ja) * 2019-01-18 2023-08-29 アセポディア バイオテクノロジーズ リミテッド 新規ｃｄ１６＋ナチュラルキラーおよびｃｄ１６＋ナチュラルキラー細胞の培養方法
EP3941492A4 (de) * 2019-03-19 2023-05-03 Ramot at Tel-Aviv University Ltd. T-zelle, die einen fc-gamma-rezeptor exprimiert, und verfahren zur verwendung davon
EP3712257A1 (de) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modifizierte natürliche killerzellen mit erhöhter resistenz gegen zelltod
EP3942022A1 (de) 2019-03-21 2022-01-26 ONK Therapeutics Limited Modifizierte immuneffektorzellen mit erhöhter resistenz gegen zelltod
MA55761A (fr) 2019-04-23 2022-03-02 Sanofi Sa Formulations et anticorps anti-cd38
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CA3115917A1 (en) * 2019-08-01 2021-02-04 Nantkwest, Inc. Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells
CA3149810A1 (en) 2019-08-15 2021-02-18 Nantbio, Inc. Tgf-beta trap
WO2021101467A1 (en) * 2019-11-19 2021-05-27 Acibadem Mehmet Ali̇ Aydinlar Üni̇versi̇tesi̇ A method for redesign and expansion of nk92 cells for use in immunotherapy
EP4061928A4 (de) 2019-11-20 2023-12-20 ImmunityBio, Inc. Zellvermittelte transiente abgabe von immunverstärkenden molekülen in die tumormikroumgebung
EP3914699A4 (de) * 2019-12-09 2023-03-29 ImmunityBio, Inc. Screening von zellklonen, die polygene transgene exprimieren, durch nichtantibiotische abhängige positive selektion
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
CN115315510A (zh) * 2020-01-28 2022-11-08 免疫生物公司 靶向egfr超家族受体的嵌合抗原受体修饰的nk-92细胞
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
CN113603787B (zh) * 2020-05-04 2023-05-23 英诺康生物医药科技(广州)有限公司 一种非分泌型的人白细胞介素15及应用
EP4168438A4 (de) * 2020-06-22 2024-07-10 Univ Ramot Proteinmodule mit mehreren untereinheiten, zellen zur expression davon und verwendungen davon
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
EP4108247A1 (de) 2021-06-23 2022-12-28 Ostravska univerzita Harnvorläuferzellen zur verwendung in der krebstherapie
WO2023081163A1 (en) 2021-11-02 2023-05-11 Immunitybio, Inc. Natural killer cells for chordoma therapy
EP4180049A1 (de) 2021-11-16 2023-05-17 Ostravska univerzita Therapeutische zusammensetzung zur krebsbehandlung
US20230323395A1 (en) * 2021-12-15 2023-10-12 Homology Medicines, Inc. Methods and compositions for the production of adeno-associated virus
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3733919A (en) * 1971-09-20 1973-05-22 Adjustable eccentric bearing mountings background
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5767077A (en) * 1988-05-27 1998-06-16 Applied Research Systems Ars Holding N.V. Human Fc-γ receptor III
WO1989011490A1 (en) * 1988-05-27 1989-11-30 Schering Biotech Corporation HUMAN Fcgamma RECEPTOR III
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US7038031B1 (en) * 1989-07-28 2006-05-02 Sloan-Kettering Institute For Cancer Research DNA encoding FcγR receptor protein on NK cells
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
KR100373813B1 (ko) 1994-05-02 2003-10-08 베른트 그로너 이관능성단백질,그의제조및용도
KR100343214B1 (ko) * 1995-03-28 2002-11-13 삼성에스디아이 주식회사 전계방출소자의제조방법
US5830725A (en) 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AU7267398A (en) 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use
US20030026780A1 (en) * 2001-07-18 2003-02-06 Hood Leroy E. Innate immunity mediated methods of treating pathological conditions
US20050031613A1 (en) * 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
US7618617B2 (en) * 2002-05-31 2009-11-17 L'oreal Aqueous hair treatment compositions, thickened with an amphiphilic linear block copolymer
KR101375153B1 (ko) 2003-07-02 2014-03-18 위니베르시따 디 제노바 Ｐａｎ-ｋｉｒ2ｄｌ ｎｋ-수용체 항체 및 진단 및치료에서의 그 사용 방법
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
DK2112162T3 (da) * 2004-07-10 2015-02-23 Fox Chase Cancer Ct Genetisk modificerede humane naturlige dræbercellelinjer
JP5295568B2 (ja) 2005-01-06 2013-09-18 ノヴォ ノルディスク アー／エス Ｋｉｒ結合剤およびその使用方法

Also Published As

Publication number Publication date
EP1771471B1 (de) 2009-09-16
DK2801583T3 (en) 2018-07-16
AU2005277831B2 (en) 2012-11-22
EP2921500B1 (de) 2023-08-30
EP2801583A1 (de) 2014-11-12
US20060292156A1 (en) 2006-12-28
HK1215269A1 (zh) 2016-08-19
CA3052445C (en) 2023-08-22
EP3406631B1 (de) 2022-06-29
ES2955952T3 (es) 2023-12-11
EP2921500A1 (de) 2015-09-23
DK3406631T3 (da) 2022-08-29
EP2112162B1 (de) 2015-01-14
CA2572938C (en) 2019-10-15
US20100086996A1 (en) 2010-04-08
EP3406631A1 (de) 2018-11-28
WO2006023148A8 (en) 2006-05-04
EP2801583B1 (de) 2018-04-25
US9150636B2 (en) 2015-10-06
US20080247990A1 (en) 2008-10-09
US20160067356A1 (en) 2016-03-10
WO2006023148A2 (en) 2006-03-02
US20230372545A1 (en) 2023-11-23
US20130040386A1 (en) 2013-02-14
PT2921500T (pt) 2023-09-25
AU2005277831A1 (en) 2006-03-02
CA2572938A1 (en) 2006-03-02
US20100086486A1 (en) 2010-04-08
EP2112162A1 (de) 2009-10-28
DK2921500T5 (da) 2024-10-14
US20240016957A1 (en) 2024-01-18
EP1771471A2 (de) 2007-04-11
DK2921500T3 (da) 2023-09-18
ES2925912T3 (es) 2022-10-20
CA3052445A1 (en) 2006-03-02
HK1203975A1 (en) 2015-11-06
US7618817B2 (en) 2009-11-17
US8313943B2 (en) 2012-11-20
WO2006023148A3 (en) 2006-08-03
US9181322B2 (en) 2015-11-10
DK2112162T3 (da) 2015-02-23
ES2678094T3 (es) 2018-08-08
PL2921500T3 (pl) 2024-02-05
ATE443084T1 (de) 2009-10-15
AU2005277831A2 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
HK1215269A1 (zh) 基因修飾的人自然殺傷細胞系
ECSP056117A (es) Ligandos de receptores de cannabinoides y sus usos
IL186986A0 (en) Compositions and methods for modulating immune responses
ATE475669T1 (de) Einen modifizierten t-zellen-rezeptor exprimierende zellen
CR7875A (es) Variantes de inmunoglobina y usos de esto
DK1786439T3 (da) Fremgangsmåder til aktivering af NKT-celler
ATE373081T1 (de) Zelllinie
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
ATE542920T1 (de) Modifiziertes menschliches wachstumshormon
NO20091064L (no) Antistoffer mot IL-17A
TW200531679A (en) Methods of modulating cytokine activity; related reagents
NO20054078D0 (no) Humane antistoffer spesifikke for Interleukin 15 (IL15).
LU91989I2 (fr) Bydureon
GB0304068D0 (en) Substances
BRPI0508629A (pt) trilho lateral para uso com um suporte para paciente
GT200000200A (es) Compuestos de 2,4-diamino-pirimidina utiles como supresores de inmunidad.
ATE389670T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
GT200300199A (es) Indoles 2,7-sustituidos
ATE396977T1 (de) 2-amino-benzimidazolderivate und ihre verwendung als modulatoren calciumaktivierter kaliumkanäle mit geringer leitfähigkeit
CA2466778A1 (en) Flexible seat mount for chair seat bottom
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
ATE412010T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
EA200870177A1 (ru) Новый гликозилированный вариант fsh d3n
CY1110846T1 (el) Διαμορφωτες υποδοχεων της προγεστερονης του τυπου πυριδοοξαζεπινης
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του

Legal Events

Date Code Title Description
8363 Opposition against the patent